Cue Biopharma Overview

  • Founded

  • 2014

Founded
  • Status

  • Public

  • Employees

  • 52

Employees
  • Stock Symbol

  • CUE

Stock Symbol
  • Share Price

  • $4.11

  • (As of Friday Closing)

Cue Biopharma General Information

Description

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.

Contact Information

Website
www.cuebiopharma.com
Formerly Known As
ImaGen Biopharma
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Other Healthcare Technology Systems
Stock Exchange
NAS
Primary Office
  • 40 Guest Street
  • Boston, MA 02135
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cue Biopharma Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.11 $4.06 $2.18 - $5.12 $175M 43.2M 234K -$1.35

Cue Biopharma Financials Summary

In Thousands,
USD 		TTM 31-Mar-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 97,138 83,100 295,216 295,181
Revenue 432 1,245 14,941 3,154
EBITDA (49,910) (51,419) (43,712) (45,043)
Net Income (51,864) (53,010) (44,161) (44,785)
Total Assets 81,682 91,283 83,401 99,534
Total Debt 18,705 19,316 10,053 7,146
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cue Biopharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cue Biopharma‘s full profile, request access.

Request a free trial

Cue Biopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biolo
Discovery Tools (Healthcare)
Boston, MA
52 As of 2022
00000
0000 0000-00-00
00000000 00000

000000

exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute
0000000000000
South San Francisco, CA
000 As of 0000
00000
0.000 0000-00-00
00000000 00000

000000

it esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidata
0000 000000000
Houston, TX
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cue Biopharma Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Allogene Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
00000000 000000000 Formerly VC-backed Houston, TX 00 00000 000000000 00000
0000 000000 Formerly VC-backed Santa Monica, CA 0000 00000 000000&0 00000
000000 00000000000 Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 0000000000.
You’re viewing 5 of 11 competitors. Get the full list »

Cue Biopharma Patents

  • 136

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 4

    Granted

  • 28

    Pending

  • 000

    Expiring in next 12 mo

Cue Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3174130-A1 Tgf-beta polypeptides Pending 23-Nov-2020 000000000
CA-3174142-A1 T-cell modulatory polypeptides with conjugation sites and methods of use thereof Pending 06-Nov-2020 0000000000
AU-2021309842-A1 T-cell modulatory polypeptides with conjugation sites and methods of use thereof Pending 14-Jul-2020 000000000000
CA-3174097-A1 T-cell modulatory polypeptides with conjugation sites and methods of use thereof Pending 14-Jul-2020 000000000000
EP-4182465-A2 T-cell modulatory polypeptides with conjugation sites and methods of use thereof Pending 14-Jul-2020 C07K14/70539
To view Cue Biopharma’s complete patent history, request access »

Cue Biopharma Executive Team (12)

Name Title Board Seat Contact Info
Daniel Passeri JD Chief Executive Officer & Board Member
Anish Suri Chief Scientific Officer & President
Kerri-Ann Millar Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Patricia Nasshorn Executive
Colin Sandercock General Counsel, Legal & Secretary, Administration
You’re viewing 5 of 12 executive team members. Get the full list »

Cue Biopharma Board Members (13)

Name Representing Role Since
Aaron Fletcher Ph.D Self Board Member 000 0000
Barry Simon MD Cue Biopharma Board Member 000 0000
Daniel Passeri JD Cue Biopharma Chief Executive Officer & Board Member 000 0000
Frank Morich Ph.D Self Chairman & Board Member 000 0000
Frederick Driscoll Self Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Cue Biopharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cue Biopharma ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

34.39 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 14,912

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 965

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 443

Rank

00.00

Percentile

To view Cue Biopharma’s complete esg history, request access »